OBJECTIVE: The aim of this study was to evaluate antiviral properties of blackberry extract against herpes simplex virus type 1 (HSV-1) in vitro. STUDY DESIGN: HSV-infected oral epithelial (OKF6) cells and cell-free virus suspensions were treated with blackberry extract (2.24-1,400 μg/mL), and virus yield and infectivity were quantified by direct plaque assay. RESULTS: Blackberry extract ≥56 μg/mL inhibited HSV-1 replication in oral epithelial cells by >99% (P < .005). Concentrations ≥280 μg/mL were antiviral when the extract was added after virus adsorption and entry. Exposure of cell-free virus to ≥280 μg/mL blackberry extract for 15 minutes at room temperature was virucidal (P = .0002). The virucidal effects were not due to pH changes at concentrations up to 1,500 μg/mL. CONCLUSIONS: Blackberry extract inhibited the early stages of HSV-1 replication and had potent virucidal activity. These properties suggest that this natural fruit extract could provide advantage as a topical prophylactic/therapeutic agent for HSV infections.
OBJECTIVE: The aim of this study was to evaluate antiviral properties of blackberry extract against herpes simplex virus type 1 (HSV-1) in vitro. STUDY DESIGN:HSV-infected oral epithelial (OKF6) cells and cell-free virus suspensions were treated with blackberry extract (2.24-1,400 μg/mL), and virus yield and infectivity were quantified by direct plaque assay. RESULTS: Blackberry extract ≥56 μg/mL inhibited HSV-1 replication in oral epithelial cells by >99% (P < .005). Concentrations ≥280 μg/mL were antiviral when the extract was added after virus adsorption and entry. Exposure of cell-free virus to ≥280 μg/mL blackberry extract for 15 minutes at room temperature was virucidal (P = .0002). The virucidal effects were not due to pH changes at concentrations up to 1,500 μg/mL. CONCLUSIONS: Blackberry extract inhibited the early stages of HSV-1 replication and had potent virucidal activity. These properties suggest that this natural fruit extract could provide advantage as a topical prophylactic/therapeutic agent for HSV infections.
Authors: M A Dickson; W C Hahn; Y Ino; V Ronfard; J Y Wu; R A Weinberg; D N Louis; F P Li; J G Rheinwald Journal: Mol Cell Biol Date: 2000-02 Impact factor: 4.272
Authors: Spotswood L Spruance; Robert Nett; Thomas Marbury; Ray Wolff; James Johnson; Theodore Spaulding Journal: Antimicrob Agents Chemother Date: 2002-07 Impact factor: 5.191
Authors: O A González; C Escamilla; R J Danaher; J Dai; J L Ebersole; R J Mumper; C S Miller Journal: J Periodontal Res Date: 2012-07-19 Impact factor: 4.419